Compare HTLD & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTLD | DNA |
|---|---|---|
| Founded | 1978 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.7M | 835.7M |
| IPO Year | 1995 | 2020 |
| Metric | HTLD | DNA |
|---|---|---|
| Price | $10.56 | $12.83 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 6 | 3 |
| Target Price | ★ $11.80 | $8.00 |
| AVG Volume (30 Days) | 603.1K | ★ 2.4M |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $805,709,000.00 | $170,155,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.10 | $13.05 |
| P/E Ratio | $144.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.00 | $5.37 |
| 52 Week High | $16.64 | $18.22 |
| Indicator | HTLD | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 46.22 | 56.28 |
| Support Level | $9.35 | $6.75 |
| Resistance Level | $11.48 | $13.97 |
| Average True Range (ATR) | 0.49 | 1.37 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 43.15 | 66.95 |
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.